Trinity Biotech (TRIB) Non-Current Receivables (2009 - 2025)

Trinity Biotech's Non-Current Receivables history runs 17 years deep, the most recent figure standing at $10.9 million for Q2 2025.

• In Q2 2025, Non-Current Receivables fell 37.65% year-over-year to $10.9 million; the TTM figure through Jun 2025 stood at $10.9 million (down 37.65% YoY), while the FY2024 annual figure was $16.1 million, up 15.57% from the prior year.
• Non-Current Receivables came in at $10.9 million for Q2 2025 at Trinity Biotech, down from $16.1 million in the prior quarter.
• In the past five years, Non-Current Receivables ranged from a high of $21.2 million in Q3 2024 to a low of $10.9 million in Q2 2025.
• A 5-year average of $15.8 million and a median of $15.9 million in 2022 frame the typical range for Non-Current Receivables.
• Across the five-year window, Non-Current Receivables soared 40.5% in 2024 and tumbled 37.65% in 2025, its largest moves.
• Trinity Biotech's Non-Current Receivables stood at $16.1 million in 2021, then fell by 2.25% to $15.8 million in 2022, then dropped by 11.76% to $13.9 million in 2023, then climbed by 15.57% to $16.1 million in 2024, then plunged by 32.19% to $10.9 million in 2025.
• According to Business Quant data, Non-Current Receivables over the past three periods registered $10.9 million, $16.1 million, and $21.2 million for Q2 2025, Q4 2024, and Q3 2024 respectively.

Peer Comparison